| Completed | 1 | 3 | US | Eculizumab, Soliris | Johns Hopkins University, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe | 08/23 | 09/23 | | |
NCT05863442: Comparative PK, Safety, Tolerability, Immunogenicity, and PD Profile Study of TUR03 and Soliris in Healthy Participants |
|
|
| Recruiting | 1 | 120 | RoW | Soliris 300 MG in 30 ML Injection, TUR03 300 MG in 30 ML Injection | Turgut Ardika PTY LTD | Healthy | 07/24 | 10/24 | | |
